Invitrogen

Cdc25A Monoclonal Antibody (DCS-120)

高级验证

This Antibody was verified by Cell treatment to ensure that the antibody binds to the antigen stated.

1个已发表图片

8 篇参考文献

查看其他28个Cdc25A抗体

说明书

实验方案

技术支持

说明书

实验方案

技术支持

Cdc25A Antibody in Immunocytochemistry (ICC/IF)

图: 1 / 9

Cdc25A Antibody (MA5-13794) in ICC/IF

Immunofluorescence analysis of Cdc25A was performed using 70% confluent log phase HeLa cells treated with Hydroxyurea (1mM for 10 min). The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 15 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with Cdc25A Monoclonal Antibody (DCS-120) (Product # MA5-13794) at 5 µg/mL concentration in 0.1% BSA, incubated at 4 degree celsius overnight (Panel a: green). Nuclei (Panel b: blue) were stained with ProLong™ Diam... View More

Cdc25A Antibody in Immunohistochemistry (Paraffin) (IHC (P))

Cdc25A Antibody in Immunoprecipitation (IP)

Product Image Gallery

产品信息

MA5-13794

应用

建议稀释比

已发表文章

免疫印迹 (WB)

1-2 µg/mL

查看6篇已发表文章 6篇已发表文章

免疫组化 (IHC)

查看1篇已发表文章 1篇已发表文章

免疫组化（石蜡） (IHC (P))

Assay-dependent

免疫细胞化学 (ICC/IF)

5 µg/mL

查看1篇已发表文章 1篇已发表文章

免疫沉淀 (IP)

2 µg/mg protein lysate

产品规格

种属反应

Human, Mouse, Rat

已发表种属

Human

宿主/亚型

Mouse / IgG2a

分类

Monoclonal

类型

Antibody

克隆号

DCS-120

抗原

Purified recombinant CDC25A

偶联物

Unconjugated Unconjugated Unconjugated

形式

Liquid

浓度

0.2 mg/mL

纯化类型

Protein A

保存液

PBS, pH 7.4, with 0.2% BSA

内含物

15mM sodium azide

保存条件

4° C

运输条件

Ambient (domestic); Wet ice (international)

RRID

AB_10980530

产品详细信息

MA5-13794 targets CDC25A in IP, IHC (P) and WB applications and shows reactivity with Human and Rat samples.

The MA5-13794 immunogen is purified recombinant CDC25A.

靶标信息

CDC25a is a member of the CDC25 family of phosphatases. Three CDC25 genes are present in human cells: CDC25A, CDC25B, and CDC25C. These three genes function at different phases of the cell cycle. CDC25a is required for progression through G1 and S phases of the cell cycle. CDC25a activates the cyclin-dependent kinase CDC2 by removing two phosphate groups. CDC25A is specifically degraded in response to DNA damage, which prevents cells with chromosomal abnormalities from progressing through cell division. CDC25A is an oncogene, although its exact role in oncogenesis has not been demonstrated.

仅用于科研。不用于诊断过程。未经明确授权不得转售。

Product References

Androgen Receptor, Although Not a Specific Marker For, Is a Novel Target to Suppress Glioma Stem Cells as a Therapeutic Strategy for Glioblastoma.

Frontiers in oncology

Zhao N,Wang F,Ahmed S,Liu K,Zhang C,Cathcart SJ,DiMaio DJ,Punsoni M,Guan B,Zhou P,Wang S,Batra SK,Bronich T,Hei TK,Lin C,Zhang C

Published figure using Cdc25A monoclonal antibody (Product # MA5-13794) in Western Blot

Tue Jun 08 00:00:00 EDT 2021

The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors.

Scientific reports

Tormo E,Ballester S,Adam-Artigues A,Burgués O,Alonso E,Bermejo B,Menéndez S,Zazo S,Madoz-Gúrpide J,Rovira A,Albanell J,Rojo F,Lluch A,Eroles P

MA5-13794 was used in Western Blotting to analyse the involvement of the miRNA-449 family in the response to doxorubicin.

Fri Mar 29 00:00:00 EDT 2019

Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress.

Oncotarget

Zhang Y,Lai J,Du Z,Gao J,Yang S,Gorityala S,Xiong X,Deng O,Ma Z,Yan C,Susana G,Xu Y,Zhang J

MA513794 was used in western blot to describe how a CHK1 inhibitor reduces the growth of radioresistant breast cancer cells

Tue Jun 07 00:00:00 EDT 2016

A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.

Oncotarget

Sakurikar N,Thompson R,Montano R,Eastman A

MA5-13794 was used in western blot to report that inappropriate activation of CDK2 in S phase affects checkpoint kinase 1 inhibitor sensitivity in a subset of cell lines

Tue Jan 12 00:00:00 EST 2016

CDC25A protein stability represents a previously unrecognized target of HER2 signaling in human breast cancer: implication for a potential clinical relevance in trastuzumab treatment.

Neoplasia (New York, N.Y.)

Brunetto E,Ferrara AM,Rampoldi F,Talarico A,Cin ED,Grassini G,Spagnuolo L,Sassi I,Ferro A,Cuorvo LV,Barbareschi M,Piccinin S,Maestro R,Pecciarini L,Doglioni C,Cangi MG

MA5-13794 was used in immunohistochemistry to study the expression of CDC25A in HER2-positive breast cancer and the correlation between CDC25A levels and trastuzumab sensitivity